CD8A and lung carcinoma: Previously we have demonstrated that ex vivo expanded human peripheral blood T cells expressing CD3, without CD4, CD8, and NK T cell marker expression, termed double negative T (DNT) cells, have potent activity against lung cancer and leukemia cells in patient-derived xenograft (PDX) models [22–25].